Jennifer Pope
Family · Robertsdale, ALNPI 1720477151
Payments from drug & device makers
Across 394 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Bayer$805
- Lilly USA, LLC$750
- GSK$602
- AstraZeneca$449
- AbbVie$349
- plus $3K from 26 others
What the payments were for
- Food & beverage$6,52199%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 82 | $1,073 |
| Bayer | 43 | $805 |
| Lilly USA, LLC | 49 | $750 |
| GSK | 38 | $602 |
| AstraZeneca | 19 | $449 |
| AbbVie | 18 | $349 |
| Pfizer | 20 | $306 |
| Novartis | 19 | $302 |
| Johnson & Johnson | 13 | $214 |
| Amgen | 13 | $207 |
| Amarin Pharma, Inc. | 8 | $168 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $160 |
| Otsuka America Pharmaceutical, Inc. | 6 | $142 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $139 |
| Exact Sciences | 8 | $130 |
| Xeris Pharmaceuticals, Inc. | 5 | $110 |
| Lundbeck LLC | 5 | $87 |
| Teva Pharmaceuticals USA, Inc. | 5 | $79 |
| Esperion Therapeutics, Inc. | 5 | $76 |
| Biohaven Pharmaceuticals, Inc. | 3 | $55 |
| Paratek Pharmaceuticals, Inc. | 3 | $50 |
| Insulet Corporation | 2 | $47 |
| Radius Health, Inc. | 2 | $39 |
| Dexcom, Inc. | 3 | $38 |
| Viiv Healthcare Company | 1 | $30 |
| Abbott | 2 | $30 |
| Sanofi Pasteur Inc. | 1 | $26 |
| Medtronic | 2 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Eisai Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$6,555 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 202 | $227,860 |
| OzempicSemaglutide | 82 | $102,621 |
| JardianceEmpagliflozin | 83 | $78,504 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $67,695 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $61,833 |
| JanuviaSitagliptin Phosphate | 44 | $32,802 |
| TrulicityDulaglutide | 16 | $32,357 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $30,884 |
| Repatha SureclickEvolocumab | 42 | $30,033 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $27,872 |
| EliquisApixaban | 19 | $20,954 |
| XareltoRivaroxaban | 23 | $18,218 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $17,441 |
| KerendiaFinerenone | 11 | $14,014 |
| FarxigaDapagliflozin Propanediol | 18 | $12,635 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $750 | $260,217218 claims |
| Novo NordiskOzempic | $1,073 | $102,62182 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat | $14 | $97,812106 claims |
| GSKTrelegy Ellipta | $602 | $67,69579 claims |
| PfizerEliquis | $306 | $20,95419 claims |
| Johnson & JohnsonXarelto | $214 | $18,21823 claims |
| BayerKerendia | $805 | $14,01411 claims |
| AstraZenecaFarxiga | $449 | $12,63518 claims |
| AbbVieSynthroid | $349 | $89416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.
Other family in Robertsdale
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.